Autolus Therapeutics (AUTL) Q4 2023 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2023 earnings summary
9 Nov, 2026Executive summary
Obe-cel’s U.S. BLA was accepted with a November 16, 2024 PDUFA date; an EMA marketing application was submitted, and launch preparation continued.
FELIX analyses showed stronger event-free survival with lower leukemic burden and low rates of high-grade CRS/ICANS; pooled long-term follow-up reported an 80.6% ORR in R/R B-ALL.
Year-end cash was $239.6M; February financing and the BioNTech collaboration generated $600M in gross proceeds to support launch and pipeline development.
Financial highlights
FY23 operating expenses, net, were $179.7M vs. $143.4M in FY22; R&D was $130.5M vs. $117.4M and G&A was $46.7M vs. $31.9M.
FY23 net loss was $208.4M vs. $148.8M in FY22; basic and diluted loss per share was $1.20 vs. $1.57.
FY23 license revenue was $1.7M vs. $6.2M in FY22; interest income was $13.5M vs. $1.7M and interest expense was $45.1M vs. $8.9M.
Cash and cash equivalents were $239.6M at December 31, 2023, vs. $382.4M at December 31, 2022.
Outlook and guidance
FDA action on obe-cel is targeted for November 16, 2024; an MHRA application filing was planned for H2 2024, with U.S. launch preparation and center onboarding underway.
2024 milestones included obe-cel FELIX updates at ASCO, EHA and ASH; initial Phase 1 SLE data were expected in late 2024.
Initial AUTO8 MCARTY study data were expected during 2024; cash and February financing proceeds were expected to fund launch preparations, pipeline development and autoimmune studies.
Latest events from Autolus Therapeutics
- AUCATZYL scales commercially as margin gains and new indications build the next growth drivers.AUTL
Jefferies Global Healthcare Conference - AUCATZYL growth and expanding obe-cel trials broaden the commercial opportunity.AUTL
Corporate presentation - AUCATZYL revenue rose 95%, gross margin reached 57%, and FY2026 guidance is at least $150M.AUTL
Q3 2026 - IPO-funded cash supports expanding T-cell trials, but losses and clinical risks remain significant.AUTL
Q4 2018 - A £113.5m loss funded a growing T-cell pipeline, with COVID-19 clouding timelines.AUTL
Q4 2019 - Cash runway extended to May 2023 as clinical development drives continued losses.AUTL
Q4 2021 - Licensing growth and a £316.3m cash balance offset a wider loss, with funding needed beyond June 2024.AUTL
Q4 2022 - Resale registration for 3.5M ADSs linked to a warrant, supporting T cell therapy expansion.AUTL
Registration filing - Q2 2026 revenue surged 119% year-over-year, with gross margin at 55% and guidance raised.AUTL
Q2 2026